Those are currently headed by C-CAR031, a GPC3-targeting therapy that has started clinical testing in liver cancer, and STEAP2-directed AZD0754, which is still in early-stage development as a ...

除了外部BD获得的CAR-T产品外，阿斯利康还自研或合作开发了CAR-T产品AZD7003（靶向GPC3）、AZD0754（靶向Steap2）和AZD6422（靶向Claudin18.2）。 虽然阿斯利康在CAR-T赛道入局并不算早，但其正在用实际行动展示押注下一代CAR-T技术的决心。那么，关于阿斯利康押注的体内 ...

1 Institute of Oncology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China 2 Internal Medicine, The Second People’s Hospital of Nantong, Nantong, China ...

Among them, STEAP1, STEAP2 and F77 have been used as new targets for CAR-T therapy of PCa, and clinical studies of CAR-T cells targeting STEAP1 and STEAP2 have also begun. F77, a distinctive ...